ALX Oncology Holdings closed at $1.36 on Nov 4, up 5.43%, 47.7% below its 52-week closing high. Volume of 950.0K shares was 0.64× its 20-day average (below normal).
Split-adjusted performance: +22.5% over one month, -34.9% over six months, -13.4% over one year.
Short interest was 6.0M shares at the Oct 15 settlement, up 5.3% from the prior report (6.5% of float, 3.6 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ALXOALX Oncology Holdings | $1.36 | +5.43% | −34.9% | — | — | — | $188.1M | |
| BBOTBridgeBio Oncology Therapeutics | $2.30 | −0.86% | −72.4% | — | — | — | $184.4M | Compare |
| AKBAAkebia Therapeutics | $0.6947 | −4.28% | −53.1% | −21.4% | −18.1% | — | $192.5M | Compare |
| WHWKWhitehawk Therapeutics | $3.17 | +2.26% | −23.6% | — | — | — | $180.7M | Compare |
| TRDAEntrada Therapeutics | $5.06 | +7.20% | −68.4% | −53.9% | −4762.0% | — | $197.0M | Compare |
| NAGENiagen Bioscience | $2.52 | +6.78% | −49.3% | −4.3% | 3.2% | 12.5 | $199.4M | Compare |
| UPBUpstream Bio | $3.70 | +9.14% | −59.7% | −17.5% | −5136.1% | — | $202.7M | Compare |
| ORMPOramed Pharmaceuticals | $4.13 | +3.25% | +5.4% | — | — | 1.0 | $171.8M | Compare |
| RNACCartesian Therapeutics | $6.82 | +6.40% | −18.2% | −100.0% | — | — | $206.3M | Compare |
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
